Physician profile
Angela Chen
NPI 1679635403
$1,254.24
in general payments reported to CMS, 2019-2025
19 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.84 · 2022: $284 · 2023: $242 · 2024: $317 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $320.55 | 2021-2024 | Wegovy |
| Bausch Health US, LLC | $213.76 | 2022-2025 | Aplenzin |
| Axsome Therapeutics, INC. | $168.98 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $100.05 | 2025 | Spravato |
| Exact Sciences Corporation | $78.01 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $51.31 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $42.21 | 2023 | Shingrix, Arexvy |
| Acella Pharmaceuticals, LLC | $38.31 | 2023 | NP Thyroid 60 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.00 | 2025 | Caplyta |
| Lilly USA, LLC | $32.82 | 2023-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $28.58 | 2021 | |
| Neurocrine Biosciences, INC. | $25.88 | 2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $22.97 | 2024 | Strensiq |
| Eisai INC. | $20.30 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.19 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.76 | 2023 | Proclaim |
| Abbvie INC. | $16.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.59 | 2023 | Xifaxan |
| Horizon Therapeutics Plc | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.